These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 23622932)

  • 21. Alefacept: its safety profile, off-label uses, and potential as part of combination therapies for psoriasis.
    Scheinfeld N
    J Dermatolog Treat; 2007; 18(4):197-208. PubMed ID: 17671880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of therapeutic interchange for biologic therapies.
    Flood J; Mihalik C; Fleming RR; Strober BE; Zucker DR; Burgoyne DS
    Manag Care; 2007 Jan; 16(1):51-62. PubMed ID: 17285813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Managed care's perspective on treatment of plaque psoriasis.
    Sullivan TJ
    Manag Care; 2003 May; 12(5 Suppl):14-7; discussion 20-1. PubMed ID: 18564554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Off-label use of biologic agents in the treatment of dermatosis, Part 1: infliximab and adalimumab].
    Díaz-Ley B; Guhl G; Fernández-Herrera J
    Actas Dermosifiliogr; 2007 Dec; 98(10):657-78. PubMed ID: 18035024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity of therapeutics: a matter of efficacy and safety.
    Nechansky A; Kircheis R
    Expert Opin Drug Discov; 2010 Nov; 5(11):1067-79. PubMed ID: 22827745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biologic therapy in inflammatory bowel disease.
    Theede K; Dahlerup JF; Fallingborg J; Hvas CL; Kjeldsen J; Munck LK; Nordgaard-Lassen I;
    Dan Med J; 2013 Jun; 60(6):B4652. PubMed ID: 23743116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment and management of psoriasis with nail involvement: a focus on biologic therapy.
    Langley RG; Daudén E
    Dermatology; 2010; 221 Suppl 1():29-42. PubMed ID: 20733313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An evidence-based review of skin cancer rates on biologic therapies.
    Kamangar F; Neuhaus IM; Koo JY
    J Dermatolog Treat; 2012 Aug; 23(4):305-15. PubMed ID: 22188512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutics and immune-mediated skin disease.
    Gordon KB; Satoskar R
    Curr Dir Autoimmun; 2008; 10():359-72. PubMed ID: 18460896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
    Weinberg JM; Saini R
    Cutis; 2003 Jan; 71(1):25-9. PubMed ID: 12553627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Statistical considerations for calculation of immunogenicity screening assay cut points.
    Hoffman D; Berger M
    J Immunol Methods; 2011 Oct; 373(1-2):200-8. PubMed ID: 21906599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clobetasol propionate spray 0.05% add-on therapy to a stable regimen of biologic treatment in patients with moderate to very severe plaque psoriasis.
    Feldman SR; Koo JY; Johnson LA; Preston NJ
    Cutis; 2009 Oct; 84(4 Suppl):25-32. PubMed ID: 19916299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [What's new in dermatological therapy?].
    Paul C
    Ann Dermatol Venereol; 2007 Dec; 134 Suppl 1():8S64-75. PubMed ID: 18675142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. From laboratory to clinic: rationale for biologic therapy.
    Mehlis S; Gordon KB
    Dermatol Clin; 2004 Oct; 22(4):371-7, vii-viii. PubMed ID: 15450333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Etanercept provides a more physiological approach in the treatment of psoriasis.
    Altomare G; Ayala F; Berardesca E; Chimenti S; Giannetti A; Girolomoni G; Lotti T; Martini P; Peserico A; Guerra AP; Vena GA
    Dermatol Ther; 2008 Oct; 21 Suppl 2():S1-14. PubMed ID: 18837727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of cyclosporine in dermatology: part I.
    Amor KT; Ryan C; Menter A
    J Am Acad Dermatol; 2010 Dec; 63(6):925-46; quiz 947-8. PubMed ID: 21093659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Could anti IL12/23 therapy replace anti-TNF biologics?
    Ionescu MA; Lipozencić J
    Acta Dermatovenerol Croat; 2009; 17(3):166-9. PubMed ID: 19818214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Scientific and regulatory considerations on the immunogenicity of biologics.
    Shankar G; Shores E; Wagner C; Mire-Sluis A
    Trends Biotechnol; 2006 Jun; 24(6):274-80. PubMed ID: 16631266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Innovative therapeutics in pediatric dermatology.
    Gelmetti C; Frasin A; Restano L
    Dermatol Clin; 2010 Jul; 28(3):619-29. PubMed ID: 20510770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Future perspectives in the treatment of psoriasis: news in biological therapies].
    Diamantino F; Ferreira A
    Acta Med Port; 2011; 24(6):997-1004. PubMed ID: 22713194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.